Study design. *Patients who did not receive infusions for clinical reasons. **Exclusion criteria for the landmark analyses were: death, relapse, severe acute GVHD and CMV reactivation occurring prior to day 28. ***CTL trial recruits for whom a CTL product was available but who did not receive an infusion for clinical reasons were included in the CTL cohort; analysis was on an intention-to-treat basis.